Study of radioactive treatment for FAP-positive advanced tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new radioactive treatment (177Lu-OncoFAP-23) alone or combined with an immunotherapy (L19-IL2) for people with advanced solid tumors that have a specific protein called FAP. It's for patients whose cancer has grown despite standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer has continued to grow even after trying standard treatments available for your tumor type.
- You must have a special PET scan that shows your tumor has a protein called FAP.
- You are 18 or older and not pregnant or breastfeeding.
- You have at least one measurable tumor that can be seen on a CT scan (and that spot hasn't been treated with radiation before).
- You should be able to take care of yourself (up and about most of the day) and have a life expectancy of at least 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that uses a radioactive medicine called [177Lu]Lu-RTX-2358 combined with immunotherapy (a type of drug that helps your immune system fight cancer). It is for people with advanced non-small cell lung cancer whose tumors have a specific marker called FAP.
This trial tests a radioactive drug called 177Lu-JH04 for people whose tumors have high levels of a protein called FAP. The drug targets and treats advanced tumors that have stopped responding to other treatments.
This trial tests a new radioactive drug (225Ac-FAPI-XT) for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called FAP found on many cancer cells, which may help deliver radiation directly to the tumor.
This trial tests an investigational drug called [177Lu]Lu-XT117, which delivers a small dose of radiation directly to cancer cells that have a specific protein called FAP. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
This trial tests a new radioactive drug, Lutetium-177 FAP-75, for people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and deliver radiation directly to cancer cells, potentially slowing tumor growth.
Hear when a new FAP trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.